Aadi Bioscience, the Nasdaq-listed biopharmaceutical company focused on genetically defined cancers, has appointed Marcy Graham to the newly created role of senior vice president of IR and corporate communications.
Most recently, Graham served as vice president of corporate affairs at Poseida Therapeutics. Prior to that, she worked as vice president of IR and corporate communications at Mirati Therapeutics. In total, she has more than 20 years’ experience in IR and communications roles within the healthcare industry.
‘We are delighted to welcome Marcy to the team, as she brings extensive experience to the senior role of investor relations and corporate communications and a strong history of relationship building with investors and other key external audiences,’ says Neil Desai, founder, president and CEO of Aadi.
‘She has helped transition multiple companies from private to public and we look forward to her contribution as we broaden our investor base and expand our corporate presence.’
In August 2021, Aadi closed a merger with Nasdaq-listed Aerpio Pharmaceuticals, with the combined company taking on the name Aadi Bioscience. Later in the year, the business received its first approval from the Food and Drug Administration for its lead product FYARRO, which targets a rare form of sarcoma.
‘I am excited to join Aadi at this pivotal stage in the company’s development, following the transition to the public markets and then achieving its first commercial product approval while furthering pipeline advancements for precision therapies in oncology,’ says Graham, who holds an MBA from the Anderson School of Management.
‘I look forward to working with the team to convey Aadi’s vision as we grow and achieve the milestones ahead.’